Search

Your search keyword '"Peschanski, Marc"' showing total 597 results
Start Over Author "Peschanski, Marc"
597 results on '"Peschanski, Marc"'

6. Human Pluripotent Stem Cell-derived Cortical Neurons for High Throughput Medication Screening in Autism: A Proof of Concept Study in SHANK3 Haploinsufficiency Syndrome

Author

Darville, Hélène, Poulet, Aurélie, Rodet-Amsellem, Frédérique, Chatrousse, Laure, Pernelle, Julie, Boissart, Claire, Héron, Delphine, Nava, Caroline, Perrier, Anselme, Jarrige, Margot, Cogé, Francis, Millan, Mark J., Bourgeron, Thomas, Peschanski, Marc, Delorme, Richard, and Benchoua, Alexandra

Published
2016
Full Text
View/download PDF

8. Supplementary Data from Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma

Author

Guillamo, Jean-Sébastien, primary, de Boüard, Sophie, primary, Valable, Samuel, primary, Marteau, Lena, primary, Leuraud, Pascal, primary, Marie, Yannick, primary, Poupon, Marie-France, primary, Parienti, Jean-Jacques, primary, Raymond, Eric, primary, and Peschanski, Marc, primary

Published
2023
Full Text
View/download PDF

11. In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide Metformin

Author

Laustriat, Delphine, Gide, Jacqueline, Barrault, Laetitia, Chautard, Emilie, Benoit, Clara, Auboeuf, Didier, Boland, Anne, Battail, Christophe, Artiguenave, François, Deleuze, Jean-François, Bénit, Paule, Rustin, Pierre, Franc, Sylvia, Charpentier, Guillaume, Furling, Denis, Bassez, Guillaume, Nissan, Xavier, Martinat, Cécile, Peschanski, Marc, and Baghdoyan, Sandrine

Published
2015
Full Text
View/download PDF

14. ESDR579 - Clinical grade human pluripotent stem cells derived engineered skin substitutes promote keratinocytes wound closure in vitro

Author

Domingues, Sophie, primary, Darle, Annabelle, primary, Masson, Yolande, primary, Saidani, Manoubia, primary, Lagoutte, Emilie, primary, Bejanariu, Ana, primary, Coutier, Julien, primary, Eren Ayata, Raif, primary, Bouschbacher, Marielle, primary, Peschanski, Marc, primary, Lemaitre, Gilles, primary, and Baldeschi, Christine, primary

Published
2022
Full Text
View/download PDF

17. Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase <scp>II</scp> Trial

Author

Bachoud-Lévi, Anne-Catherine, Schramm, Catherine, Remy, Philippe, Aubin, Ghislaine, Blond, Serge, Bocket, Laurence, Brugières, Pierre, Calvas, Fabienne, Calvier, Elisabeth, Cassim, François, Challine, Dominique, Gagou, Clarisse Scherer, De Langavant, Laurent Cleret, Collier, Francis, Cottencin, Olivier, David, Philippe, Damier, Philippe, Delliaux, Marie, Delmaire, Christine, Delval, Arnaud, Démonet, Jean‐François, Descamps, Philippe, Gaura, Véronique, Gohier, Bénédicte, Goldman, Serge, Haddad, Bassam, Izopet, Jacques, Jeny, Roland, Kerr-Conte, Julie, Krystowiak, Pierre, Lalanne, Christophe, Lavisse, Sonia, Lefaucheur, Jean‐Pascal, Lemoine, Laurie, Levivier, Marc, Lotterie, Jean‐Albert, Lunel‐Fabiani, Françoise, Maison, Patrick, Massager, Nicolas, Massart, Renaud, Menei, Philippe, Montero‐Menei, Claudia, Neveu, Isabelle, Parant, Olivier, Pautot, Vivien, Payoux, Pierre, Péréon, Yann, Rialland, Amandine, Rosser, Anne, Rouard, Hélène HR, Schmitz, David, Simonetta‐Moreau, Marion, Simonin, Clémence, Slama, Hichem, Sol, Jean‐Christophe, Supiot, Frédéric, Tanguy, Jean‐Yves, Tenenbaum, Liliane, Verny, Christophe, Youssov, Katia, Peschanski, Marc, Audureau, Etienne, Palfi, Stéphane, Hantraye, Philippe, Centre de référence maladie de Huntington, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), IMRB - 'NeuroPsychologie Interventionnelle' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris sciences et lettres (PSL), Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), AOM00139 and AOM04021 Direction de la Recherche Clinique, Association Française contre les Myopathies., Collaborators : on behalf the Multicentric Intracerebral Grafting in Huntington's Disease Group : Catherine Schramm, Philippe Remy, Ghislaine Aubin, Serge Blond, Laurence Bocket, Pierre Brugières, Fabienne Calvas, Elisabeth Calvier, François Cassim, Dominique Challine, Clarisse Scherer Gagou, Laurent Cleret de Langavant, Francis Collier, Olivier Cottencin, Philippe David, Philippe Damier, Marie Delliaux, Christine Delmaire, Arnaud Delval, Jean-François Démonet, Philippe Descamps, Véronique Gaura, Bénédicte Gohier, Serge Goldman, Bassam Haddad, Jacques Izopet, Roland Jeny, Julie Kerr-Conte, Pierre Krystowiak, Christophe Lalanne, Sonia Lavisse, Jean-Pascal Lefaucheur, Laurie Lemoine, Marc Levivier, Jean-Albert Lotterie, Françoise Lunel-Fabiani, Patrick Maison, Nicolas Massager, Renaud Massart, Philippe Menei, Claudia Montero-Menei, Isabelle Neveu, Olivier Parant, Vivien Pautot, Pierre Payoux, Yann Pereon, Amandine Rialland, Anne Rosser, Hélène Rouard, David Schmitz, Marion Simonetta-Moreau, Clémence Simonin, Hichem Slama, Jean-Christophe Sol, Frédéric Supiot, Jean-Yves Tanguy, Liliane Tenenbaum, Christophe Verny, Katia Youssov, Marc Peschanski, Etienne Audureau, Stéphane Palfi, Philippe Hantraye., and Montero-Menei, claudia

Subjects
0301 basic medicine, medicine.medical_specialty, Neurology, Huntington s disease, MIG-' HD, Cell- and Tissue-Based Therapy, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Disease, law.invention, 03 medical and health sciences, 0302 clinical medicine, Huntington's disease, Randomized controlled trial, law, Internal medicine, medicine, Humans, Stage (cooking), Adverse effect, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, business.industry, phase 2 trial, Neurodegenerative Diseases, Sciences bio-médicales et agricoles, medicine.disease, Confidence interval, Transplantation, Huntington Disease, 030104 developmental biology, Neurology (clinical), cell therapy, business, 030217 neurology & neurosurgery
Abstract

Background\ud Huntington's disease is a rare, severe, inherited neurodegenerative disease in which we assessed the safety and efficacy of grafting human fetal ganglionic eminence intrastriatally.\ud \ud Methods\ud Patients at the early stage of the disease were enrolled in the Multicentric Intracerebral Grafting in Huntington's Disease trial, a delayed‐start phase II randomized study. After a run‐in period of 12 months, patients were randomized at month 12 to either the treatment group (transplanted at month 13–month 14) or the control group and secondarily treated 20 months later (month 33–month 34). The primary outcome was total motor score compared between both groups 20 months postrandomization (month 32). Secondary outcomes included clinical, imaging, and electrophysiological findings and a comparison of pregraft and postgraft total motor score slopes during the entire study period (month 0–month 52) regardless of the time of transplant.\ud \ud Results\ud Of 54 randomized patients, 45 were transplanted; 26 immediately (treatment) and 19 delayed (control). Mean total motor score at month 32 did not differ between groups (treated controls difference in means adjusted for M12: +2.9 [95% confidence interval, −2.8 to 8.6]; P = 0.31). Its rate of decline after transplantation was similar to that before transplantation. A total of 27 severe adverse events were recorded in the randomized patients, 10 of which were related to the transplant procedure. Improvement of procedures during the trial significantly decreased the frequency of surgical events.We found antihuman leucocytes antigen antibodies in 40% of the patients.\ud \ud Conclusion\ud No clinical benefit was found in this trial. This may have been related to graft rejection. Ectopia and high track number negatively influence the graft outcome. Procedural adjustments substantially improved surgical safety. (ClinicalTrials.gov NCT00190450.) © 2020 International Parkinson and Movement Disorder Society

Published
2020
Full Text
View/download PDF

24. Clinical Grade Human Pluripotent Stem Cell-Derived Engineered Skin Substitutes Promote Keratinocytes Wound Closure In Vitro

Author

Domingues, Sophie, primary, Darle, Annabelle, additional, Masson, Yolande, additional, Saidani, Manoubia, additional, Lagoutte, Emilie, additional, Bejanariu, Ana, additional, Coutier, Julien, additional, Ayata, Raif Eren, additional, Bouschbacher, Marielle, additional, Peschanski, Marc, additional, Lemaitre, Gilles, additional, and Baldeschi, Christine, additional

Published
2022
Full Text
View/download PDF

30. Recurrent genomic instability of chromosome 1q in neural derivatives of human embryonic stem cells

Author

Varela, Christine, Denis, Jerome Alexandre, Polentes, Jerome, Feyeux, Maxime, Aubert, Sophie, Champon, Benoite, Pietu, Genevieve, Peschanski, Marc, and Lefort, Nathalie

Subjects
Physiological aspects, Genetic aspects, Research, Risk factors, Health aspects, Chromosomal instability syndromes -- Risk factors -- Research, Embryonic stem cells -- Physiological aspects -- Genetic aspects -- Research, Gene mutation -- Health aspects, Gene mutations -- Health aspects
Abstract

Introduction Whether pluripotent stem cell derivatives can eventually be used widely for therapeutic purpose after the first ongoing clinical trials (1-4) will depend upon their capacity to pass strict quality [...], Human pluripotent stem cells offer a limitless source of cells for regenerative medicine. Neural derivatives of human embryonic stem cells (hESCs) are currently being used for cell therapy in 3 clinical trials. However, hESCs are prone to genomic instability, which could limit their clinical utility. Here, we report that neural differentiation of hESCs systematically produced a neural stem cell population that could be propagated for more than 50 passages without entering senescence; this was true for all 6 hESC lines tested. The apparent spontaneous loss of evolution toward normal senescence of somatic cells was associated with a jumping translocation of chromosome 1q. This chromosomal defect has previously been associated with hematologic malignancies and pediatric brain tumors with poor clinical outcome. Neural stem cells carrying the 1q defect implanted into the brains of rats failed to integrate and expand, whereas normal cells engrafted. Our results call for additional quality controls to be implemented to ensure genomic integrity not only of undifferentiated pluripotent stem cells, but also of hESC derivatives that form cell therapy end products, particularly neural lines.

Published
2012
Full Text
View/download PDF

33. Biothérapies : des médicaments comme les autres ?

Author

Amalric, François, Bassompierre, François, Becquemont, Laurent, Cartron, Guillaume, Cellier, Dominic, Dagher, Georges, Demerens, Thierry, Dessein, Alain, Girault, Danièle, Grognet, Jean-Marc, Le Gros, Vincent, Lemoine, François, Moachon, Laurence, Pallardy, Marc, Pathak, Atul, Peschanski, Marc, Ségard, Lionel, Squiban, Patrick, Vasmant, Daniel, Vermeesch, Luc, HervéWatier, Zorzi, Pierrette, Paintaud, Gilles, Tonelli, Dominique, and Postaire, Eric

Published
2007
Full Text
View/download PDF

34. Biotherapies: Are they Just Like any Other Drugs?

Author

Amalric, François, Bassompierre, François, Becquemont, Laurent, Cartron, Guillaume, Cellier, Dominic, Dagher, Georges, Demerens, Thierry, Dessein, Alain, Girault, Danièle, Grognet, Jean-Marc, Le Gros, Vincent, Lemoine, François, Moachon, Laurence, Pallardy, Marc, Pathak, Atul, Peschanski, Marc, Ségard, Lionel, Squiban, Patrick, Vasmant, Daniel, Vermeesch, Luc, HervéWatier, Zorzi, Pierrette, Paintaud, Gilles, Tonelli, Dominique, and Postaire, Eric

Published
2007
Full Text
View/download PDF

37. Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation

Author

Martin, Caroline, Plat, Martine, Nerrière-Daguin, Véronique, Coulon, Flora, Uzbekova, Svetlana, Venturi, Eric, Condé, Françoise, Hermel, Jean-Michel, Hantraye, Philippe, Tesson, Laurent, Anegon, Ignacio, Melchior, Benoit, Peschanski, Marc, Mauff, Brigitte Le, Boeffard, Françoise, Sergent-Tanguy, Solène, Neveu, Isabelle, Naveilhan, Philippe, Soulillou, Jean-Paul, Terqui, Michel, Brachet, Philippe, and Vanhove, Bernard

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results